Investing
Brean Murray Comments on Dendreon (DNDN) Following Friday's Run-Up
Published:
Last Updated:
Brean Murray comments on Dendreon (Nasdaq: DNDN) this morning, following Friday’s 38% run-up, which they said was related to competitor’s call with a physician in the field and word Provenge Phase 3 trial results being slated for potential presentation on April 28 at the American Urological Association annual meeting. Brean Murray said neither of these changes anything fundamental about the trial outcome.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
